Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
LINC00445 is a human long intergenic non-protein coding RNA gene that does not encode a protein but rather produces a non-coding RNA transcript greater than 200 nucleotides. It is autonomously transcribed from intergenic regions in the genome[3]. Like other lincRNAs, LINC00445 is believed to participate in the fine regulation of gene expression, potentially by interacting with chromatin, regulatory proteins, and RNA molecules. Expression profiling and integrative bioinformatics studies suggest LINC00445 is differentially expressed in cancer tissues, notably lung cancer, where it may serve as a diagnostic biomarker and molecular target in tumorigenesis[2][1]. While its specific biological pathways remain under investigation, the broad family of lincRNAs is known for tissue-specific regulatory roles and involvement in disease pathogenesis[3][5]. There is currently no evidence for misspelling, ambiguity, or incorrect annotation regarding LINC00445 based on authoritative genetic and biomedical databases[1].
Not applicable (no direct-acting drugs known for this target as of current literature).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Long intergenic non-protein coding RNA 445 (LINC00445).